ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
2 |
18/05/20 |
18/05/20 |
ASX - By Stock
|
23K
|
13M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Competition? What Competition?
|
|
Yor
|
73 |
32K |
20 |
17/05/20 |
17/05/20 |
ASX - By Stock
|
73
|
32K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
MESO ... how will americans respond?
|
|
Yor
|
59 |
30K |
2 |
13/05/20 |
13/05/20 |
ASX - By Stock
|
59
|
30K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MESO ... how will americans respond?
|
|
Yor
|
59 |
30K |
17 |
13/05/20 |
13/05/20 |
ASX - By Stock
|
59
|
30K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
2 Thumbs Up for Mesoblast
|
|
Yor
|
72 |
45K |
4 |
11/05/20 |
11/05/20 |
ASX - By Stock
|
72
|
45K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
A Bigger Cash Cow for Revascor?
|
|
Yor
|
45 |
25K |
12 |
10/05/20 |
10/05/20 |
ASX - By Stock
|
45
|
25K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
2 Thumbs Up for Mesoblast
|
|
Yor
|
72 |
45K |
0 |
10/05/20 |
10/05/20 |
ASX - By Stock
|
72
|
45K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
2 Thumbs Up for Mesoblast
|
|
Yor
|
72 |
45K |
7 |
10/05/20 |
10/05/20 |
ASX - By Stock
|
72
|
45K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment
|
|
Yor
|
296 |
99K |
13 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
296
|
99K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
I'm Calling it!
|
|
Yor
|
7 |
3.7K |
13 |
24/04/20 |
24/04/20 |
ASX - By Stock
|
7
|
3.7K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Googala's 2020 Share Price Competitions
|
|
Yor
|
303 |
102K |
1 |
22/04/20 |
22/04/20 |
ASX - By Stock
|
303
|
102K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Annual end of year msb price tipping contest...returns
|
|
Yor
|
75 |
25K |
3 |
21/04/20 |
21/04/20 |
ASX - By Stock
|
75
|
25K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Inflammatory Lung Disease Outcomes For Presentation at ISCT
|
|
Yor
|
75 |
35K |
0 |
20/04/20 |
20/04/20 |
ASX - By Stock
|
75
|
35K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
UT Health hMSC trial - potentially part of CTSN?
|
|
Yor
|
7 |
3.5K |
5 |
18/04/20 |
18/04/20 |
ASX - By Stock
|
7
|
3.5K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial
|
|
Yor
|
276 |
141K |
25 |
12/04/20 |
12/04/20 |
ASX - By Stock
|
276
|
141K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Ann: US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial
|
|
Yor
|
276 |
141K |
9 |
11/04/20 |
11/04/20 |
ASX - By Stock
|
276
|
141K
|
9
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
12 |
02/04/20 |
02/04/20 |
ASX - By Stock
|
23K
|
13M
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting
|
|
Yor
|
84 |
34K |
9 |
31/03/20 |
31/03/20 |
ASX - By Stock
|
84
|
34K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
The case for Mesoblast's MSCs for ARDS
|
|
Yor
|
221 |
89K |
8 |
21/03/20 |
21/03/20 |
ASX - By Stock
|
221
|
89K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Yor
|
5.4K |
2.7M |
2 |
19/03/20 |
19/03/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Yor
|
5.4K |
2.7M |
3 |
19/03/20 |
19/03/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Yor
|
5.4K |
2.7M |
4 |
19/03/20 |
19/03/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
FDA approval process
|
|
Yor
|
27 |
165K |
10 |
13/03/20 |
13/03/20 |
ASX - By Stock
|
27
|
165K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Gilead vs Mesoblast
|
|
Yor
|
274 |
111K |
6 |
12/03/20 |
12/03/20 |
ASX - By Stock
|
274
|
111K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Yor
|
5.4K |
2.7M |
7 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Yor
|
17K |
6.8M |
11 |
04/03/20 |
04/03/20 |
ASX - By Stock
|
17K
|
6.8M
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Sidetracked
|
|
Yor
|
4 |
5.0K |
18 |
24/02/20 |
24/02/20 |
ASX - By Stock
|
4
|
5.0K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Yor
|
17K |
6.8M |
22 |
15/02/20 |
15/02/20 |
ASX - By Stock
|
17K
|
6.8M
|
22
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Yor
|
5.4K |
2.7M |
2 |
12/02/20 |
12/02/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
15 |
09/02/20 |
09/02/20 |
ASX - By Stock
|
23K
|
13M
|
15
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
20 |
08/02/20 |
08/02/20 |
ASX - By Stock
|
23K
|
13M
|
20
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
7 |
06/02/20 |
06/02/20 |
ASX - By Stock
|
23K
|
13M
|
7
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
16 |
05/02/20 |
05/02/20 |
ASX - By Stock
|
23K
|
13M
|
16
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
3 |
05/02/20 |
05/02/20 |
ASX - By Stock
|
23K
|
13M
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
9 |
01/02/20 |
01/02/20 |
ASX - By Stock
|
23K
|
13M
|
9
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
16 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
23K
|
13M
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C - quarterly
|
|
Yor
|
135 |
88K |
13 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
135
|
88K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C - quarterly
|
|
Yor
|
135 |
88K |
23 |
30/01/20 |
30/01/20 |
ASX - By Stock
|
135
|
88K
|
23
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
18 |
27/01/20 |
27/01/20 |
ASX - By Stock
|
23K
|
13M
|
18
|
|
Charts
|
MSB |
Re:
MSB Charts
|
|
Yor
|
888 |
645K |
10 |
23/01/20 |
23/01/20 |
Charts
|
888
|
645K
|
10
|
|
Charts
|
MSB |
Re:
MSB Charts
|
|
Yor
|
888 |
645K |
6 |
23/01/20 |
23/01/20 |
Charts
|
888
|
645K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Yor
|
5.4K |
2.7M |
12 |
22/01/20 |
22/01/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
12
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
20 |
21/01/20 |
21/01/20 |
ASX - By Stock
|
23K
|
13M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Presents Commercial Plans at 2020 Biotech Showcase
|
|
Yor
|
48 |
27K |
6 |
16/01/20 |
16/01/20 |
ASX - By Stock
|
48
|
27K
|
6
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
6 |
06/01/20 |
06/01/20 |
ASX - By Stock
|
23K
|
13M
|
6
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
4 |
03/01/20 |
03/01/20 |
ASX - By Stock
|
23K
|
13M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 2A
|
|
Yor
|
2 |
2.9K |
0 |
03/01/20 |
03/01/20 |
ASX - By Stock
|
2
|
2.9K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Files GvHD Clinical Efficacy and Safety Data with US FDA
|
|
Yor
|
73 |
49K |
4 |
02/01/20 |
02/01/20 |
ASX - By Stock
|
73
|
49K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
Yor
|
4.4K |
2.4M |
29 |
25/12/19 |
25/12/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
29
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DMC Completes Final Review of Phase 3 Heart Failure Trial
|
|
Yor
|
73 |
49K |
6 |
20/12/19 |
20/12/19 |
ASX - By Stock
|
73
|
49K
|
6
|
|